Department of Clinical and Experimental Medicine, Endocrinology Unit, Garibaldi Nesima Hospital, University of Catania, Via Palermo 636, 95125, Catania, Italy.
J Endocrinol Invest. 2024 Sep;47(9):2177-2184. doi: 10.1007/s40618-024-02332-3. Epub 2024 Mar 15.
Graves' ophthalmopathy (GO) is an autoimmune disease that affects orbital soft tissues and represents the most common extrathyroidal manifestation of Graves' disease (GD). The European Group of Graves' Ophthalmopathy (EUGOGO) has attempted to shed light on the European epidemiological picture of GO, suggesting that GO in newly diagnosed patients in recent years has a trend towards a less severe clinical presentation. There are no studies that focus this issue on the population of our area; we aimed to evaluate the trend of GO clinical presentation in our outpatient clinic through an observation period of 10 years.
We compared 55 consecutive patients, 11 males (F) and 44 females (M), who came to our observation from January 2005 to December 2006 [Group 1 (G1)], with 56 patients, 15 males, and 41 females, who were referred to us from 2015 to 2016 [Group 2 (G2)]. We studied the following putative predictors of GO presentation and severity: thyroid function, smoking, diabetes, hypercholesterolemia, time from GO diagnosis to referral to our thyroid centre (TGOD), sex and age.
GO severity was significantly reduced in G2 vs. G1 (p = 0.04). TGOD ≥ 3 months was related to clinical characteristics of GO (severity and Clinical Activity Score ≥ 4) and was an independent predictor of GO severity (p = 0.01). The other variables evaluated had no independent effects.
We found that GO severity at presentation was significantly reduced over a ten-year observation period (2005-2006 vs. 2015-2016) in GO patients referred to our tertiary thyroid centre. TGOD ≥ 3 months was an independent predictor of GO severity.
格雷夫斯眼病(GO)是一种影响眼眶软组织的自身免疫性疾病,是格雷夫斯病(GD)最常见的甲状腺外表现。欧洲格雷夫斯眼病专家组(EUGOGO)试图阐明近年来欧洲 GO 的流行病学特征,提示近年来新诊断的 GD 患者的 GO 临床表现呈较轻趋势。但是,针对我们所在地区人群的研究还没有。因此,我们旨在通过 10 年的观察期,评估我们的门诊 GO 临床表现的趋势。
我们比较了 2005 年 1 月至 2006 年 12 月期间来我院就诊的 55 例连续患者,其中 11 例为男性(F),44 例为女性(M)[第 1 组(G1)],与 2015 年至 2016 年就诊的 56 例患者,其中 15 例为男性,41 例为女性[第 2 组(G2)]。我们研究了以下可能影响 GO 表现和严重程度的预测因素:甲状腺功能、吸烟、糖尿病、高胆固醇血症、GO 诊断后至转诊至我院甲状腺中心的时间(TGOD)、性别和年龄。
与 G1 相比,G2 的 GO 严重程度明显降低(p=0.04)。TGOD≥3 个月与 GO 的临床特征(严重程度和临床活动评分≥4)相关,是 GO 严重程度的独立预测因素(p=0.01)。评估的其他变量没有独立影响。
我们发现,在转诊至我院甲状腺中心的 GO 患者中,经过十年的观察(2005-2006 年与 2015-2016 年),GO 的临床表现严重程度显著降低。TGOD≥3 个月是 GO 严重程度的独立预测因素。